TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32087152

Group type: EXPERIMENTAL
Intervention: PrEP initiation
Number of subjects: 70379

Group type: EXPERIMENTAL
Intervention: PrEP engagement at week 4
Number of subjects: 70379

Group type: EXPERIMENTAL
Intervention: Medication refills at week 4
Number of subjects: 70379

Group type: EXPERIMENTAL
Intervention: Self-reported adherence at week 4
Number of subjects: 70379

Group type: EXPERIMENTAL
Intervention: PrEP engagement at week 72
Number of subjects: 70379

Group type: EXPERIMENTAL
Intervention: Medication refills at week 72
Number of subjects: 70379

Group type: EXPERIMENTAL
Intervention: Self-reported adherence at week 72
Number of subjects: 70379

Group type: EXPERIMENTAL
Intervention: Self-reported adherence with tenofovir concentrations
Number of subjects: 70379

Group type: EXPERIMENTAL
Intervention: Adverse events related to PrEP
Number of subjects: 70379
Study: 32087304

Group type: EXPERIMENTAL
Intervention: Lenvatinib and entinostat combination
Number of subjects: 0
Study: 32087715

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (50 mg for 10-<25 kg, 87.5 mg for 25-<50 kg)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (with/without methotrexate and/or low-dose corticosteroids)
Number of subjects: 219
Study: 32087733

Group type: EXPERIMENTAL
Intervention: PCV + PPV23 in abatacept
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PCV + PPV23 in cDMARDs
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PCV + PPV23 in controls
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PCV + PPV23 in rituximab
Number of subjects: 108

Group type: COMPARATOR
Intervention: PCV + PPV23 in all treatment groups
Number of subjects: 108

Group type: COMPARATOR
Intervention: OPA assay in rituximab
Number of subjects: 108

Group type: COMPARATOR
Intervention: OPA assay in abatacept
Number of subjects: 108

Group type: COMPARATOR
Intervention: OPA assay in cDMARDs
Number of subjects: 108
Study: 32087839

Group type: EXPERIMENTAL
Intervention: Generalist model (BI delivered by primary care provider)
Number of subjects: 9639

Group type: COMPARATOR
Intervention: Specialist model (BI delivered by behavioral health counselor)
Number of subjects: 9639
Study: 32087995

Group type: EXPERIMENTAL
Intervention: CT Leaman score
Number of subjects: 169
Study: 32088180

Group type: EXPERIMENTAL
Intervention: Adjunctive strategies (neuromuscular blockade, prone position, extracorporeal membrane oxygenation, inhaled vasodilators, high-frequency ventilation)
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Adjunctive strategies
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Specialized adjuncts
Number of subjects: 1146
Study: 32088255

Group type: EXPERIMENTAL
Intervention: Correct Medical Condition (CMC)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Signs/Symptoms (SS)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Incorrect Medical Condition (IMC)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Calls with chief complaint description pursued
Number of subjects: 433

Group type: COMPARATOR
Intervention: Calls without chief complaint description pursued
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Calls with SS chief complaints
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Calls with IMC chief complaints
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Calls with CMC chief complaints
Number of subjects: 433
Study: 32088322

Group type: EXPERIMENTAL
Intervention: GLS-6150 (4 mg, 3 mg, or 6 mg/vaccination, administered 4 times at 4-week intervals, followed by a 6 mg boost at 24 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GLS-6150
Number of subjects: 20
Study: 32088663

Group type: EXPERIMENTAL
Intervention: Avacopan
Number of subjects: 300

Group type: COMPARATOR
Intervention: Prednisone (active control)
Number of subjects: 300
Study: 32088879

Group type: EXPERIMENTAL
Intervention: Glycemia overtreatment (HbA1c < 6.5% with ≥ 2 oral antihyperglycemics or insulin)
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Blood pressure overtreatment (SBP < 120 mmHg or DBP < 65 mmHg with ≥ 2 drugs)
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Glycemia undertreatment (HbA1c > 9%)
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Blood pressure undertreatment (SBP > 150 mmHg or DBP > 90 mmHg)
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Deintensification of glycemia treatment
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Intensification of glycemia treatment
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Deintensification of BP treatment
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Intensification of BP treatment
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Predictors of glycemia overtreatment
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Predictors of BP overtreatment
Number of subjects: 1264
Study: 32088984

Group type: EXPERIMENTAL
Intervention: Invasive hemodynamic evaluation through right heart catheterization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive cardiopulmonary exercise test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive right heart catheterization protocol
Number of subjects: 0
Study: 32089047

Group type: EXPERIMENTAL
Intervention: Hyperoxia treatment, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32089164

Group type: EXPERIMENTAL
Intervention: CCR5 antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: maraviroc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: homozygous for the CCR5△32 allele
Number of subjects: 0
Study: 32089640

Group type: EXPERIMENTAL
Intervention: Ganetespib (200 mg/m) and Sirolimus (oral mTOR inhibitor)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ganetespib and Sirolimus
Number of subjects: 20
Study: 32089783

Group type: EXPERIMENTAL
Intervention: Health resort treatment
Number of subjects: 0
Study: 32089871

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of anti-VEGF
Number of subjects: 467
Study: 32090289

Group type: EXPERIMENTAL
Intervention: SSE education during screening mammography
Number of subjects: 280

Group type: COMPARATOR
Intervention: Positive screening mammogram
Number of subjects: 280

Group type: COMPARATOR
Intervention: History of indoor tanning
Number of subjects: 280
Study: 32090339

Group type: EXPERIMENTAL
Intervention: OCT1 wild-type pediatric patients
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Neonates with MRP3 genotypes
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Hepatic MRP3 protein level
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: OCT1 *1/*3 genotyped patients older than 1 year
Number of subjects: 142
Study: 32090594

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block (SPGB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no SPGB)
Number of subjects: 42
Study: 32090636

Group type: EXPERIMENTAL
Intervention: RVd-ASCT (lenalidomide/bortezomib/dexamethasone with autologous stem cell transplantation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RVd-alone (lenalidomide/bortezomib/dexamethasone without autologous stem cell transplantation)
Number of subjects: 0
Study: 32090650

Group type: EXPERIMENTAL
Intervention: T45BID
Number of subjects: 3043

Group type: EXPERIMENTAL
Intervention: T90QD
Number of subjects: 3043

Group type: COMPARATOR
Intervention: C75QD
Number of subjects: 3043
Study: 32090723

Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern (MDP)
Number of subjects: 10713

Group type: COMPARATOR
Intervention: Western dietary pattern (WDP)
Number of subjects: 10713
Study: 32090747

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 17
Study: 32091493

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 4 or 6 mg/kg every 8 hours by 1-hour intravenous infusion plus intravenous ampicillin and optional aminoglycoside for 48 hours-14 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 6 mg/kg every 8 hours
Number of subjects: 11
Study: 32091590

Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg intravenous)
Number of subjects: 6
Study: 32091965

Group type: EXPERIMENTAL
Intervention: Longer breastfeeding duration during infancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer breastfeeding duration
Number of subjects: 0
Study: 32092139

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg/d in combination with cytarabine/daunorubicin induction on days 1 to 7, followed by dasatinib 100 mg/d on days 6 to 26 for 4 courses, and then dasatinib 100 mg/d for 12 months after achieving complete remission.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg/d
Number of subjects: 61
Study: 32092928

Group type: EXPERIMENTAL
Intervention: Higher cardiorespiratory fitness (CRF)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Lower sedentary behavior (SB), higher moderate-to-vigorous physical activity (MVPA), and higher CRF
Number of subjects: 757

Group type: COMPARATOR
Intervention: Low CRF
Number of subjects: 757
Study: 32093185

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 0
Study: 32093506

Group type: EXPERIMENTAL
Intervention: Noninvasive remote monitoring using a disposable multisensor patch
Number of subjects: 100
Study: 32093514

Group type: EXPERIMENTAL
Intervention: Bioabsorbable sirolimus-eluting metallic scaffold (Magmaris)
Number of subjects: 70
Study: 32093525

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32093649

Group type: EXPERIMENTAL
Intervention: Gemcitabine/erlotinib treatment with skin rash
Number of subjects: 376

Group type: COMPARATOR
Intervention: Gemcitabine/erlotinib treatment without skin rash
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Gemcitabine/erlotinib treatment with skin rash grade ≥ 2
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Gemcitabine/erlotinib treatment in patients > 65 years
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Gemcitabine/erlotinib treatment
Number of subjects: 376
Study: 32094063

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks in 6-week cycles
Number of subjects: 53
Study: 32094138

Group type: EXPERIMENTAL
Intervention: JNJ-56136379 (JNJ-6379)
Number of subjects: 0
Study: 32094925

Group type: EXPERIMENTAL
Intervention: AAV8-coRPGR (adeno-associated viral vector encoding codon-optimized human RPGR)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: AAV8-coRPGR
Number of subjects: 18

Group type: COMPARATOR
Intervention: Steroid treatment for subretinal inflammation
Number of subjects: 18
Study: 32095087

Group type: EXPERIMENTAL
Intervention: Severe OSA patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controls (AHI <5/h)
Number of subjects: 20
Study: 32095161

Group type: EXPERIMENTAL
Intervention: Ready-to-drink SPMC oral solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split-dose, low-volume sodium picosulfate, magnesium oxide, and citric acid powder for oral solution
Number of subjects: 0
Study: 32095545

Group type: EXPERIMENTAL
Intervention: Short course radiotherapy (SCRT, 5 × 5 Gy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Long course radiotherapy (LCRT, 25 × 2 Gy)
Number of subjects: 10
Study: 32095777

Group type: EXPERIMENTAL
Intervention: Single intravitreal injection of aflibercept
Number of subjects: 0
Study: 32095919

Group type: EXPERIMENTAL
Intervention: 4 MBq/kg dosage group
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 MBq/kg dosage group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Furosemide administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interrater reliability
Number of subjects: 0
Study: 32096433

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 0
Study: 32096654

Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system which wirelessly transmits results to compatible insulin pumps
Number of subjects: 0
Study: 32096708

Group type: EXPERIMENTAL
Intervention: Multiparametric response map (mPRM) measurements using volume-matched CT and hyperpolarized helium 3
Number of subjects: 0
Study: 32097091

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg and bevacizumab 15 mg/kg given intravenously every 3 weeks (phase II)
Number of subjects: 48
Study: 32097119

Group type: EXPERIMENTAL
Intervention: Telerehabilitation combined with exergames (Jintronix exergame and Reacts Application) for 2 months.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional therapy (graded repetitive arm supplementary program; GRASP) with no supervision for 2 months.
Number of subjects: 52
Study: 32097181

Group type: EXPERIMENTAL
Intervention: Systemic n-3 fatty acid levels (DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic n-3 fatty acid levels (other measures)
Number of subjects: 0
Study: 32097182

Group type: EXPERIMENTAL
Intervention: Orthokeratology contact lenses (Emerald, Euclid Systems)
Number of subjects: 29
Study: 32097754

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: Sedentary Behaviour (SB)
Number of subjects: 1935

Group type: EXPERIMENTAL
Intervention: Combined PA and SB effect
Number of subjects: 1935
Study: 32098607

Group type: EXPERIMENTAL
Intervention: Prior anticoagulation
Number of subjects: 5645

Group type: COMPARATOR
Intervention: No prior anticoagulation
Number of subjects: 5645
Study: 32098623

Group type: EXPERIMENTAL
Intervention: Oral Ty21a (4 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not immunized)
Number of subjects: 0
Study: 32098855

Group type: EXPERIMENTAL
Intervention: Autoantibodies against the prion protein
Number of subjects: 124
Study: 32098866

Group type: EXPERIMENTAL
Intervention: Ultrasensitive copeptin (CPus)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Ultrasensitive procalcitonin (PCTus)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Midregional pro-adrenomedullin
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Midregional pro-atrial natriuretic peptide (MRproANP)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: C-terminal pro-endothelin
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: All biomarkers
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model
Number of subjects: 573

Group type: COMPARATOR
Intervention: Clinical parameters
Number of subjects: 573
Study: 32098874

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX), administered in a minimum of two to a maximum of three cycles, specific dosage and duration not detailed.
Number of subjects: 13
Study: 32099317

Group type: EXPERIMENTAL
Intervention: Blinq screener
Number of subjects: 100

Group type: COMPARATOR
Intervention: Adaptica 2WIN
Number of subjects: 100
Study: 32099661

Group type: EXPERIMENTAL
Intervention: Chlorhexidine locking device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32099663

Group type: EXPERIMENTAL
Intervention: Reduced-exertion, high-intensity interval training (REHIT)
Number of subjects: 40
Study: 32099847

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554
Study: 32099953

Group type: EXPERIMENTAL
Intervention: Wearable camera device for passive food image capture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-reported dietary intake methods
Number of subjects: 0
Study: 32100020

Group type: EXPERIMENTAL
Intervention: Embryo Transfer (ET) performed by operators with varying experience
Number of subjects: 19824

Group type: COMPARATOR
Intervention: Worst operator performance
Number of subjects: 19824

Group type: COMPARATOR
Intervention: Best operator performance
Number of subjects: 19824

Group type: EXPERIMENTAL
Intervention: Operator's experience
Number of subjects: 19824
Study: 32100175

Group type: EXPERIMENTAL
Intervention: Propofol administered via target controlled infusion (TCI) with EEG-derived bispectral index (BIS) monitoring.
Number of subjects: 80
Study: 32100191

Group type: EXPERIMENTAL
Intervention: Consumption of canned and cooked tomatoes more than four times a week
Number of subjects: 27934

Group type: EXPERIMENTAL
Intervention: Continuous variable of canned and cooked tomato consumption (64 g/day)
Number of subjects: 27934

Group type: EXPERIMENTAL
Intervention: 24-h dietary recall intake of 71 g/day canned and cooked tomato product
Number of subjects: 27934

Group type: COMPARATOR
Intervention: Uncalibrated multivariable-adjusted competing risk analyses
Number of subjects: 27934
Study: 32100192

Group type: EXPERIMENTAL
Intervention: Gla-300 (Glargine 300 U/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDeg-100 (Degludec 100 U/mL)
Number of subjects: 0
Study: 32100619

Group type: EXPERIMENTAL
Intervention: Hopkins Verbal Learning Test-Revised (HVLT-R)
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Demographic variables (age, gender, education)
Number of subjects: 19114
Study: 32101140

Group type: EXPERIMENTAL
Intervention: Multimodal treatment strategy including wound care (98.9%), antibiotherapy (77.5%), discontinuation of Vitamin K antagonists (VKA) (70.8%), intravenous sodium thiosulfate (65.2%)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Surgical debridement, distal CUA, localization to the lower limbs, and non calcium-based phosphate binders
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Risk factors for developing CUA among dialysis patients
Number of subjects: 89
Study: 32101275

Group type: EXPERIMENTAL
Intervention: CKAT (Composite Kernel Association Test)
Number of subjects: 0
Study: 32101614

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DT group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triple Therapy (TT group)
Number of subjects: 40
Study: 32102167

Group type: EXPERIMENTAL
Intervention: 2.67 g/day agmatine sulfate (AgmaSet)
Number of subjects: 0
Study: 32102566

Group type: EXPERIMENTAL
Intervention: Final kissing balloon (FKI)
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Short overlap FKI
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: 2-stent strategy with FKI
Number of subjects: 2742
Study: 32102577

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 52
Study: 32102585

Group type: EXPERIMENTAL
Intervention: Child caregiving load (number of children living with the mother, presence of children's internalizing, externalizing, or medical problems)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Child internalizing and medical problems
Number of subjects: 172
Study: 32102676

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (target-controlled infusion using the Schneider model)
Number of subjects: 35
Study: 32102950

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-based therapy (alone or in combination with chemotherapy)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: pTMB ≥ 16 mut/Mb
Number of subjects: 66
Study: 32103260

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily with food
Number of subjects: 17
Study: 32103268

Group type: EXPERIMENTAL
Intervention: Cluster-1 (high T-cell PD-1 expression)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Cluster-3 (hyperinflamed profile)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Cluster-2
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Cluster-3
Number of subjects: 211
Study: 32103273

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 215
Study: 32103499

Group type: EXPERIMENTAL
Intervention: Post-remission strategies with allotransplant
Number of subjects: 158

Group type: COMPARATOR
Intervention: Post-remission strategies without allotransplant
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Wild-type or mono-allelic mutated CCAAT/enhancer-binding protein alpha (CEBPA)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Mutated NRAS
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Mutated colony-stimulating factor 3 receptor (CSF3R)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Positive measurable residual disease (MRD)-test after the second consolidation cycle
Number of subjects: 158
Study: 32103756

Group type: EXPERIMENTAL
Intervention: Ketogenic Mediterranean diet with phytoextracts (KEMEPHY)
Number of subjects: 14
Study: 32103882

Group type: EXPERIMENTAL
Intervention: Low viscosity silicone oil (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High viscosity silicone oil (Group 2)
Number of subjects: 100
Study: 32103970

Group type: EXPERIMENTAL
Intervention: Peripheral endovascular device intervention
Number of subjects: 404
Study: 32104059

Group type: EXPERIMENTAL
Intervention: N-methyl-D-aspartate antagonists (intravenous ketamine and oral memantine)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous steroids
Number of subjects: 41
Study: 32104962

Group type: EXPERIMENTAL
Intervention: Simultaneous acoustic vibrations and positive expiratory pressure applied to the nasal cavity twice daily over 5 weeks
Number of subjects: 40
Study: 32105124

Group type: EXPERIMENTAL
Intervention: Emotion regulation strategies in individuals with psychosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emotion regulation strategies in nonclinical controls
Number of subjects: 0
Study: 32105128

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Both CBT and PFPP
Number of subjects: 138
Study: 32105212

Group type: EXPERIMENTAL
Intervention: Faster oxygen desaturation rate (FODR group: ODR > 0.37, n = 50)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Slower oxygen desaturation rate (ODR ≤ 0.37, n = 52)
Number of subjects: 102
Study: 32105293

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) administered via intramuscular injections on days 1 and 2 and then 6 months later.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) administered via intramuscular injections.
Number of subjects: 64
Study: 32105576

Group type: EXPERIMENTAL
Intervention: Therapeutic miRNA-based inhibitory strategies
Number of subjects: 0
Study: 32105608

Group type: EXPERIMENTAL
Intervention: Nasal disease (n=98)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Extranasal disease (n=68)
Number of subjects: 166
Study: 32105622

Group type: EXPERIMENTAL
Intervention: Larotrectinib (100 mg twice daily for adults, 100 mg/m² for paediatric patients)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 159
Study: 32105713

Group type: EXPERIMENTAL
Intervention: Second-look endoscopy with biopsies
Number of subjects: 103

Group type: COMPARATOR
Intervention: Negative biopsy specimens from second-look endoscopy
Number of subjects: 103